Loss of heterozygosity at 6p21 and HLA class I expression in esophageal squamous cell carcinomas in China

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2741-2745

  Xiaogang, Zhao ^a   Qifeng, Sun ^a   Hui, Tian ^b   Bo, Cong ^a   Xingtao, Jiang ^a   Chuanliang, Peng ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; HLA class I; Immune surveillance; Loss of heterozygosity

Indexed keywords

EID: 84858163813     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Boon T, van der Bruggen P (1994). Human tumor antigens recognized by T lymphocytes. J Exp Med, 183, 725-9
2. Browning M, Dunning D (2006). HLA and cancer:implications for cancer immunotherapy and vaccination. Eur J Immunogenet, 24, 293-312.
3. Dunn GP, Bruce AT, Ikeda H, et al (2002). Cancer immunoediting:from immunosurveillance to tumor escape. Nat Immunol, 3, 702-9.
4. Dutrillaux B (1995). Pathways of chromosome alteration in human epithelial cancers. Adv Cancer Res, 67, 59-82.
5. Goldminc M, Maddern G, Le Prise E, et al (1993). Oesophagectomy by a transhiatal approach or thoracotomy:a prospective randomized trial. Br J Surg, 80, 367-70.
6. Feenstra M, Veltkamp M, Van Kuik J, et al (1999). HLA class I expression and chromosomal deletions at 6p and 15q in head neck squamous cell carcinomas. Tissue Antigens, 54, 235-45.
7. Flutter B, Gao B (2004). MHC class I antigen presentation: recentlytrimmed and well presented. Cell Mol Immunol, 1, 22-30.
8. Garrido F, Cabrera T, Accolla RS, et al (1997). HLA and cancer:12th International Histocompatibility Workshop Study. In: Charron D, editor. HLA Genetic Diversity of HLA, vol.1. Functional and Medical Implications. Paris: EDK, 445-52.
9. Hosch SB, Izbicki JR, Pichlmeier U, et al (1997). Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer, 74, 582-7.
10. Koopman LA, Mulder A, Corver WE, et al (1988). HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens, 51, 623-36
11. Mizuki N, Ando H, Kimura M, et al (2007). Nucleotide sequence analysis of the HLA class I region spanning the 273-kb segment around the HLA-B and-C genes. Genomics, 42, 55-66.
12. Nie Y, Yang G, Song Y, et al (2001). DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis, 22, 1615-23.
13. Ogino T, Shigyo H, Ishii H, et al (2006). HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res, 66, 9281-9.
14. Randerson J, Cakwell L, Jack A, et al (1996). Fluorescent polymerase chain reaction of a panel of CA repeats on chromosome 6 in the indolent phase of follicular centre cell lymphoma. Br J Cancer, 74, 942-6.
15. Real LM, Jimenez P, Canton J, et al (1998). In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. Int J Cancer, 75, 317-23.
16. Rui-Cabello F, Klein E, Garrido F (2006). MHC antigen on human tumors. Immunol Lett, 29, 181-9.
17. Tamiya G, Ota M, Katsuyama Y, et al (1998). Twenty-six new polymorphic microsatellite markers around the HLA-B,-C and -E loci in the human MHC class I region. Tissue Antigen, 51, 337-46